Effect of the dipeptide retro-analog of cholecystokinin tetrapeptide (GB-115) on the behavior of rhesus monkeys in isolation

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Introduction. The developed domestic dipeptide retro-analog of cholecystokinin (CCK) tetrapeptide (N-(6-phenylhexanoyl)-glycyltryptophan amide, compound GB-115) with antagonistic properties towards CCK1 receptors has anxiolytic activity, previously shown in preclinical and clinical studies.

Purpose of the study. Evaluation of the anxiolytic effect of GB-115 in tablet dosage form with subchronic oral administration in comparison with phenazepam in laboratory primates.

Methods. The experiment was performed on four male rhesus monkeys (Macaca mulatta) aged 5.7–6.7 years. After a 30-day period of adaptation to the conditions of individual housing, an experiment was performed with GB-115 (0.001 g tablets) and then with phenazepam (0.0005 g tablets). Both drugs were given one at a time (7 days), and then 2 tablets (7 days). Behavior was assessed by observing the object with registration according to the “Yes-No” principle of ethogram elements in the background periods, during the administration of drugs and during their withdrawal. Using enzyme immunoassay, the content of stress response biomarkers: cortisol and dehydroepiandrosterone sulfate (DHEA-S) was determined in blood serum.

Results. GB-115 (0.001 g each) and phenazepam (0.001 g each) reduced the stay of animals in the upper part of the cage compared to the background period, which indicates a decrease in the stress response. GB-115 (0.002 g each) decreased the cortisol/DHEA-S ratio. Phenazepam dose-dependently reduced serum cortisol levels without affecting DHEA-S levels; with the administration of phenazepam (0.001 g), a decrease in the cortisol/DHEA-S ratio was also recorded.

Conclusion. A positive effect of GB-115, when administered subchronically, on the weakening of the emotional stress reaction and restoration of adaptive behavior in rhesus monkeys was revealed, comparable to the effect of phenazepam, which confirms the possibility of using blockade of CCK1 receptors as one of the approaches for the treatment of anxiety disorders.

Full Text

Restricted Access

About the authors

Alla V. Panchenko

Research Institute of Medical Primatology

Author for correspondence.
Email: shmaliy.a.v@gmail.com
ORCID iD: 0000-0003-1294-751X

Leading researcher, Laboratory of Molecular Biology, Candidate of medical sciences, Assistant Professor

Russian Federation, st. Mira, p. 177, p. Vesele, Adler district, Sochi, Krasnodar region, 354376

Andrey V. Panchenko

Research Institute of Medical Primatology

Email: ando_pan@mail.ru
ORCID iD: 0000-0002-5346-7646

Chief Researcher Laboratory of Molecular Biology, Doctor of medical sciences

Russian Federation, st. Mira, p. 177, p. Vesele, Adler district, Sochi, Krasnodar region, 354376

Laura E. Pavlova

Research Institute of Medical Primatology

Email: pavlova_laura@mail.ru
ORCID iD: 0000-0002-0638-0986

Researcher Laboratory of Molecular Biology

Russian Federation, st. Mira, p. 177, p. Vesele, Adler district, Sochi, Krasnodar region, 354376

Maria F. Timina

Research Institute of Medical Primatology

Email: free_marshmallows@mail.ru
ORCID iD: 0000-0002-1916-238X

Junior researcher Laboratory of Molecular Biology

Russian Federation, st. Mira, p. 177, p. Vesele, Adler district, Sochi, Krasnodar region, 354376

Elena V. Cherkashina

Research Institute of Medical Primatology

Email: cherkashina.e78@mail.ru
ORCID iD: 0009-0008-8090-7695

Veterinarian

Russian Federation, st. Mira, p. 177, p. Vesele, Adler district, Sochi, Krasnodar region, 354376

Larisa G. Kolik

Research Institute of Pharmacology named after. V.V. Zakusova

Email: lgkolik@mail.ru
ORCID iD: 0000-0002-9847-8058

Chief researcher Laboratory for Pharmacological Regulation, Doctor of biological sciences, Professor of RAS

Russian Federation, st. Baltiyskaya, 8, Moscow, 125315

Sergey B. Seredenin

Research Institute of Pharmacology named after. V.V. Zakusova

Email: seredeninpharm@mail.ru
ORCID iD: 0000-0003-4482-9331

Scientific director, Doctor of medical sciences, Professor, Academician of RAS

Russian Federation, st. Baltiyskaya, 8, Moscow, 125315

References

  1. Rehfeld J.F. Cholecystokinin and panic disorder: Reflections on the history and some unsolved questions. Mol Basel Switz. 2021; 26 (18): 5657. doi: 10.3390/molecules26185657
  2. Гудашева Т.А., Кирьянова Е.П., Колик Л.Г., Константинопольский М.А., Середенин С.Б. Дизайн и синтез дипептидных аналогов холецистокинина-4 с анксиолитической и анксиогенной активностью. Биоорганическая Химия. 2007; 33 (4): 413–20. doi: 10.1134/s1068162007040036 [Gudasheva T.A., Kir’ianova E.P., Kolik L.G., Konstantinopol’skii M.A., Seredenin S.B. Design and synthesis of cholecystokinin-4 dipeptide analogues with anxiolytic and anxiogenic activities. Bioorg Khim. 2007; 33 (4): 413–20 (in Russian). doi: 10.1134/s1068162007040036]
  3. Kolik L., Gudasheva T.A., Seredenin S.B. P.4.004 Dipeptide anxiolytic GB-115: new receptor targets. Eur Neuropsychopharmacol. 2011; 21: 146–7. doi: 10.1016/S0924-977X(11)70177-8
  4. Колик Л.Г., Гудашева Т.А., Середенин С.Б. Об участии холецистокининовой системы в реализации анксиолитических эффектов дипептида ГБ-115. Бюллетень экспериментальной биологии и медицины. 2012; 153 (6): 828–32. [Kolik L.G., Gudasheva T.A., Seredenin S.B. Role of the cholecystokinin system in anxiolytic activity of dipeptide GB-115. Bull Exp Biol Med. 2012; 153 (6): 828–32. doi: 10.1007/s10517-012-1842-1]
  5. Колик Л.Г., Жуков В.Н., Середенин С.Б. Характер проявления антиноцицептивных и анксиолитических свойств соединения ГБ-115 в аспекте взаимодействия холецистокининовой и опиоидергической систем. Экспериментальная и клиническая фармакология. 2007; 70 (2): 8–11. [Kolik L.G., Zhukov V.N., Seredenin S.B. Manifestations of the antinociceptive and anxiolytic properties of the compound GB-115: interactions of cholecystokinin and opioid systems. Eksp Klin Farmakol. 2007; 70 (2): 8–11 (in Russian)]
  6. Колик Л.Г., Константинопольский М.А., Рыбина И.В., Поварнина П.Ю., Гудашева Т.А., Середенин С.Б. Анксиолитическая активность дипептида ГБ-115 при пероральном введении. Бюллетень экспериментальной биологии и медицины. 2013; 155 (2): 163–6. [Kolik L.G., Konstantinopolsky M.A., Ryibina I.V., Povarnina P.Y., Gudasheva T.A., Seredenin S.B. Anxiolytic activity of dipeptide GB-115 after oral administration. Bull Exp Biol Med. 2013; 155 (2): 163–6. doi: 10.1007/s10517-013-2112-6 (in Russian)]
  7. Литвин А.А., Шевченко Р.В., Колыванов Г.Б., Бочков П.О., Смирнов В.В., Раскин С.Ю., Грибакина О.Г., Жердев В.П., Колик Л.Г., Гудашева Т.А., Ивашкина Н.Ю. Оценка периода полувыведения коротких пептидных препаратов у человека по результатам фармакокинетического исследования на животных. Химико-фармацевтический журнал. 2019; 53 (8): 16–9. doi: 10.30906/0023-1134-2019-53-8-16-19 [Litvin A.A., Shevchenko R.V., Kolyvanov G.B., Bochkov P.O., Smirnov V.V., Raskin S.Yu., Grybakina O.G., Zherdev V.P., Kolik L.G., Gudasheva T.A., Ivashkina N. Yu. Interspecies extrapolation of the half-life of short peptide drugs: From animal to human pharmacokinetics. Khimiko-Farmatsevticheskii Zhurnal. 2019; 53 (8): 16–9. doi: 10.30906/0023-1134-2019-53-8-16-19 (in Russian)]
  8. Camus S.M.J, Blois-Heulin C., Li Q., Hausberger M., Bezard E. Behavioural profiles in captive-bred cynomolgus macaques: Towards monkey models of mental disorders? PLoS ONE. 2013; 8 (4): e62141. doi: 10.1371/journal.pone.0062141
  9. Незнамов Г.Г., Дорофеева О.А., Метлина М.В., Сюняков Т.С., Минаев С.В., Ивашкина Н.Ю., Мартьянов В.А., Середенин С.Б. Результаты клинического исследования нового анксиолитика, блокатора центральных холецистокининовых рецепторов. Журнал неврологии и психиатрии имени C.C. Корсакова. 2019; 119 (8): 53–60. doi: 10.17116/jnevro201911908153 [Neznamov G.G., Dorofeeva O.A., Metlina M.V., Syunyakov T.S., Minaev S.V., Ivashkina N.Yu., Martyanov V.A., Seredenin S.B. Results of a clinical study of a new anxiolytic, a blocker of central cholecystokinin receptors. Zhurnal Nevrol Psikhiatrii Im SS Korsakova. 2019; 119 (8): 53–60. doi: 10.17116/jnevro201911908153 (in Russian)]
  10. Середенин С.Б., Воронина Т.А., Незнамов Г.Г., Жердев В.П. Феназепам: 25 лет в медицинской практике. М.: Наука, 2007; 382. [Seredenin S.B., Voronina T.A., Neznamov G.G., Zherdev V.P. Phenazepam: 25 years in medical practice. M.: Nauka, 2007; 382 (in Russian)]
  11. Harro J., Põld M., Vasar E. Anxiogenic-like action of caerulein, a CCK-8 receptor agonist, in the mouse: influence of acute and subchronic diazepam treatment. Naunyn-Schmiedeberg’s Arch Pharmacol. 1990; 341: 62–7. doi: 10.1007/BF00195059
  12. Maestripieri D., Schino G., Aureli F., Troisi A. A modest proposal: displacement activities as an indicator of emotions in primates. Anim Behav. 1992; 44 (5): 967–79. doi: 10.1016/S0003-3472(05)80592-5
  13. Baker K.C. Cage position and response to humans in singly-housed rhesus macaques (Macaca mulatta). J Am Assoc Lab Anim Sci. 2020; 59 (5): 503–7. doi: 10.30802/AALAS-JAALAS-19-000115
  14. Lutz C.K., Coleman K., Worlein J., Novak M.A. Hair loss and hair-pulling in rhesus macaques (Macaca mulatta). J. Am. Assoc Lab Anim Sci JAALAS. 2013; 52 (4): 454–7.
  15. Lutz C., Well A., Novak M. Stereotypic and self-injurious behavior in rhesus macaques: A survey and retrospective analysis of environment and early experience. Am. J. Primatol. 2003; 60 (1): 1–15. doi: 10.1002/ajp.10075
  16. Goncharova N.D. The HPA axis under stress and aging: Individual vulnerability is associated with behavioral patterns and exposure time. BioEssays. 2020; 42 (9): 2000007. doi: 10.1002/bies.202000007
  17. Griebel G., Perrault G., Sanger D.J. CCK receptor antagonists in animal models of anxiety: Comparison between exploration tests, conflict procedures and a model based on defensive behaviours. Behav Pharmacol. 1997; 8 (6): 549–60. doi: 10.1097/00008877-199711000-00013
  18. Köhler C., Chan-Palay V. Cholecystokinin-octapeptide (CCK-8) receptors in the hippocampal region: a comparative in vitro autoradiographic study in the rat, monkey and the postmortem human brain. Neurosci Lett. 1988; 90 (1–2): 51–6. doi: 10.1016/0304-3940(88)90785-9
  19. Leranth C., Frotscher M., Rakic P. CCK-immunoreactive terminals form different types of synapses in the rat and monkey hippocampus. Histochemistry. 1988; 88 (3–6): 343–52. doi: 10.1007/BF00570293
  20. Staljanssens D., Azari E.K., Christiaens O., Beaufays J., Lins L., Van Camp J., Smagghe G. The CCK(-like) receptor in the animal kingdom: Functions, evolution and structures. Peptides. 2011; 32 (3): 607–19. doi: 10.1016/j.peptides.2010.11.025

Supplementary files

Supplementary Files
Action
1. JATS XML
2. Fig. 1. Experimental design. Black arrows indicate behavior assessment sessions, white arrows indicate blood collection

Download (140KB)
3. Fig. 2. Behavioral indicators of rhesus monkeys. А - group receiving GB-115, б - group receiving phenazepam; * - p<0.05 compared to background values (without the drug)

Download (189KB)

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies